Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 7;29(13):1911–1941. doi: 10.3748/wjg.v29.i13.1911

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

PMC Copyright notice

Duplex CRISPR/Cas9 ribonucleoprotein nanomedicine disrupted antigen-presentation cells and KRAS expression to treat colorectal cancer. A: Schematic illustration of preparation of nanoformulations; B: Disruption of antigen-presentation cells and KRAS expression after duplex HAPD/RNP treatment; C: In vivo luciferase expression of orthotopic CRC (left), and representative intestine images and H&E staining of intestine sections after nanomedicine treatment. Citation: Wan T, Pan Q, Liu C, Guo J, Li B, Yan X, Cheng Y, Ping Y. A Duplex CRISPR-Cas9 Ribonucleoprotein Nanomedicine for Colorectal Cancer Gene Therapy. Nano Lett 2021; 21: 9761-9771[270]. Copyright ©The Author(s) 2021. Reprinted permission from ACS Publications. The authors have obtained the permission for figure using from the ACS Publications (Supplementary material).